TORFUR

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory.

Abbreviated Prescribing information for TORFUR (Cefuroxime Axetil 250, 500mg Tablets I.P) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime. Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

INDICATIONS: Cefuroxime axetil Tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.

DOSAGE AND ADMINISTRATION: Adult dosage is usually 250 or 500 mg b.i.d. for 10days

CONTRAINDICATIONS: Hypersensitivity to cefuroxime or to any of the excipients, Patients with known hypersensitivity to cephalosporin antibiotics, History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent(penicillins, monobactams and carbapenems). **PRECAUTIONS**: Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactamantibiotics because there is a risk of cross-sensitivity. The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease, use of cefuroxime axetil may result in the overgrowth of Candida, The development of a positive Coomb's Test associated with the use of cefuroxime may interfere with cross matching of blood. **DRUG INTERACTIONS**: Concomitant use of probenicid is notrecommended. **ADVERSE REACTIONS**: *candida* overgrowth, *clostridium difficile* overgrowth, eosinophilia, positive coomb's test, thrombocytopenia, haemolyticanaemia, leukopenia (sometimes profound), drug fever, serum sickness, anaphylaxis, jarisch- herxheimer reaction, headache, dizziness, diarrhoea, nausea, abdominal pain, vomiting, pseudomembranous colitis, transient increases of hepatic enzyme levels jaundice (predominantly cholestatic), hepatitis, skin rashes, urticaria, pruritus, erythema multiforme, stevens-johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) angioneurotico edema

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ TORFUR 250,500mg /OCT-2015/01/AbPI

(Additional information is available on request)